Mucormycosis (the black fungus) during COVID-19 pandemic: growing concerns of immunosuppressive therapy and uncontrolled diabetes mellitus

M. Tanvir Islam, Masuda Parvin, Morshed Nasir


In recent days rare but aggressive fungal disease in the form of mucormycosis has emerged and become a health concern mostly for the patients suffering from severe COVID-19 infection, poorly controlled diabetes mellitus, and patients who receive immunosuppressive therapies for diseases like malignancies. Many studies have demonstrated the relationship between COVID-19, immunosuppressive therapies, diabetes mellitus, and mucormycosis. In diabetes mellitus, poor glycemic control allows the fungi to produce pathogenesis. On the other hand, immunosuppression causes compromised neutrophil function that inhibits phagocytosis and the fusion of phagolysosome. Epidemiological data has proved that the incidence of mucormycosis from a global perspective has been on the rise and it has an association with an increasing number of diabetic cases in the world. In countries like India, Nepal, and Bangladesh where the number of diabetic and cancer patients has been growing constantly, mucormycosis could be a serious health concern in near future. Much more scientific studies, statistical analysis, and engagement of health experts are needed to combat the situation.


Black fungus, Mucormycosis, COVID-19, Immunosuppression, Steroids, Diabetes mellitus immunosup

Full Text:



Hibbett DS, Binder M, Bischoff JF. A higher level phylogenetic classification of the Fungi. Mycol Res. 2007;111:509-47.

Fürbringer P. Beobachtungen über Lungenmycose beim Menschen. Virchows Arch. 1876;66:330-65.

Paltauf A. Mycosis mucorina: Ein Beitrag zur Kenntnis der menschilchen Fadenpiltzer-krankungen. Virchows Arch. Pathol. Anat. 1885;102:543-64.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F et al. Increasing Incidence of Zygomycosis (Mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15:1395-401.

Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin. Microbiol. Infect. 2009;15:2-9.

Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M et al. Healthcare-associated mucormycosis. Clin. Infect. Dis. 2012;54:S44-54.

Chakrabarti A, Das A, Mandal J, Shivaprakash MR, George VK, Tarai B et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med. Mycol. 2006;44:335-42.

Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828-38.

Vallabhaneni S, Benedict K, Derado G, Mody RK. Trends in hospitalizations related to invasive Aspergillosis and mucormycosis in the United States, 2000–2013. Open Forum Infect Dis. 2017;4:ofw268.

Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68:1791-97.

Sharma K, Banstola A, Parajuli RR. Assessment of COVID-19 Pandemic in Nepal: A Lockdown Scenario Analysis. Front Public Health. 2021;9:599280.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL et al. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. Clin Infect Dis. 2005;41:634-53.

Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance (®): Focus on mucormycosis. Mycoses. 2014;57:240-6.

Skiada A, Pagano L, Groll A, Zimmerli S, Dupont B, Lagrou K et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European confederation of medical mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859-67.

John TM, Jacob CN, Kontoyiannis DP. When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi. 2021;7:298.

Kothandaraman N, Rengaraj A, Xue B, Yew WS, Velan SS, Karnani N et al. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab. 2021;320:E139-50.

Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118:1216-24

Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep. 2020;29:22-4.

Kenned K, Daveson K, Slavin M, Van Hal S, Sorrell T, Lee A et al. Mucormycosis in Australia: Contemporary epidemiology and outcomes. Clin Microbiol Infect. 2016;22:775-81.

Whiting DR, Guariguata L, Weil C, Shaw J. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pr. 2011;94:311-21.

WHO. Global Report on Diabetes. 2016. Accessed on 20th May, 2021.

Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S et al. A multicenter observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944.e9-15.

Ibrahim A, Spellberg B, Edwards JJr. Iron acquisition: A novel prospective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21:620-5.

Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: Transferrin and iron availability. Diabetes. 1982;31:1109-14.

Rammaert B, Lanternier F, Poiree S, Kania R, Lortholary O. Diabetes and mucormycosis: a complex interplay. Diabetes Metab. 2012;38(3):193-204.

Ali Asghar S, Majid Z, Tahir F, Qadar LT, Mir S. Rhinooculo cerebral mucormycosis resistant to amphotericin B in a young patient with diabetic ketoacidosis. Cureus. 2019;11(3):e4295.

Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and Diagnosis of Mucormycosis: An Update. Journal of Fungi. 2020; 6(4):265.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E et al. Mucormycosis ECMM MSG Global Guideline Writing Group; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019;19:e405-21.

Zaman K, Rudramurthy SM, Das A, Panda N, Honnavar P, Kaur H, Chakrabarti A. Molecular diagnosis of rhino-orbito-cerebral mucormycosis from fresh tissue samples. J Med Microbiol. 2017;66:1124-29.

Millon L, LaRosa F, Lepiller Q, Legrand F, Rocchi S, Daguindau E et al. Quantitative Polymerase Chain Reaction Detection of Circulating DNA in Serum for Early Diagnosis of Mucormycosis in Immunocompromised Patients. Clin Infect Dis. 2013;56:e95-101.

Millon L, Herbrecht R, Grenouillet F, Morio F, Alanio A, Letscher-Bru V et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: Retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF). Clin Microbiol Infect. 2016;22:810.e1-8.

Springer J, Lackner M, Ensinger C, Risslegger B, Morton CO, Nachbaur D et al. Clinical evaluation of a Mucorales-specific real-time PCR assay in tissue and serum samples. J Med Microbiol. 2016;65:1414-21.

Ino K, Nakase K, Nakamura A, Nakamori Y, Sugawara Y, Miyazaki K et al. Management of Pulmonary Mucormycosis Based on a Polymerase Chain Reaction (PCR) Diagnosis in Patients with Hematologic Malignancies: A Report of Four Cases. Intern Med. 2017;56:707-11.

Tissot F, Agrawal S, Pagano L. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433-44.

Cornely OA, Arikan-Akdagli S, Dannaoui E. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis. Clin Microbiol Infect. 2014;20:5-26.

Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47:503-9.

Alastruey-Izquierdo A, Castelli MV, Cuesta I. Activity of Posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers. Antimicrob Agents Chemother. 2009;53:1686-9.

Wiederhold NP. Pharmacokinetics and safety of posaconazole delayedrelease tablets for invasive fungal infections. Clin Pharmacol. 2016;8:1-8.